The intraperitoneal LD50 in rats is 2g/kg and 65mg/kg in mice.L9545 The subcutaneous LD50 in rats is 147mg/kg and >3500mg/kg in mice.L9545 The oral LD50 in mice is 1680mg/kg.L9545 In humans, the oral TDLO in men is 9mg/kg/2W and in women is 14mg/kg/13D.L9545
Patients experiencing an overdose of prednisolone may present with gastrointestinal disturbances, insomnia, and restlessness.A187511 Overdose of oral prednisolone may be treated by gastric lavage or inducing vomiting if the overdose was recent, as well as supportive and symptomatic therapy.L9449 Chronic overdosage may be treated by dose reduction or treating patients on alternate days.L9449 An overdose by the ophthalmic route is not expected to cause problems.L9449
Prednisolone is a glucocorticoid similar to cortisol used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.A187463
Prednisolone was granted FDA approval on 21 June 1955.L9431
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Denosumab | The risk or severity of adverse effects can be increased when Denosumab is combined with Prednisolone. |
| Peginterferon alfa-2a | The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Prednisolone. |
| Interferon alfa-n1 | The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Prednisolone. |
| Interferon alfa-n3 | The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Prednisolone. |
| Peginterferon alfa-2b | The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Prednisolone. |
| Interferon gamma-1b | The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Prednisolone. |
| Interferon alfa-2a | The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Prednisolone. |
| Aldesleukin | The risk or severity of adverse effects can be increased when Aldesleukin is combined with Prednisolone. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Prednisolone. |
| Pegaspargase | The risk or severity of adverse effects can be increased when Pegaspargase is combined with Prednisolone. |
| Interferon beta-1b | The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Prednisolone. |
| Interferon alfacon-1 | The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Prednisolone. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Prednisolone. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Prednisolone. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Prednisolone. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Prednisolone. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Prednisolone. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Prednisolone. |
| Alefacept | The risk or severity of adverse effects can be increased when Alefacept is combined with Prednisolone. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Prednisolone. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Prednisolone. |
| Interferon alfa-2b | The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Prednisolone. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Prednisolone. |
| Phenylalanine | The risk or severity of adverse effects can be increased when Phenylalanine is combined with Prednisolone. |
| Cladribine | Prednisolone may increase the immunosuppressive activities of Cladribine. |
| Carmustine | The risk or severity of adverse effects can be increased when Carmustine is combined with Prednisolone. |
| Amsacrine | The risk or severity of adverse effects can be increased when Amsacrine is combined with Prednisolone. |
| Bleomycin | The risk or severity of adverse effects can be increased when Bleomycin is combined with Prednisolone. |
| Chlorambucil | The risk or severity of adverse effects can be increased when Chlorambucil is combined with Prednisolone. |
| Raltitrexed | The risk or severity of adverse effects can be increased when Raltitrexed is combined with Prednisolone. |
| Mitomycin | The risk or severity of adverse effects can be increased when Mitomycin is combined with Prednisolone. |
| Bexarotene | The risk or severity of adverse effects can be increased when Bexarotene is combined with Prednisolone. |
| Floxuridine | The risk or severity of adverse effects can be increased when Floxuridine is combined with Prednisolone. |
| Tioguanine | The risk or severity of adverse effects can be increased when Tioguanine is combined with Prednisolone. |
| Dexrazoxane | The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Prednisolone. |
| Streptozocin | The risk or severity of adverse effects can be increased when Streptozocin is combined with Prednisolone. |
| Trifluridine | The risk or severity of adverse effects can be increased when Trifluridine is combined with Prednisolone. |
| Gemcitabine | The risk or severity of adverse effects can be increased when Gemcitabine is combined with Prednisolone. |
| Epirubicin | The risk or severity of adverse effects can be increased when Epirubicin is combined with Prednisolone. |
| Chloramphenicol | The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Prednisolone. |
| Lenalidomide | The risk or severity of adverse effects can be increased when Lenalidomide is combined with Prednisolone. |
| Altretamine | The risk or severity of adverse effects can be increased when Altretamine is combined with Prednisolone. |
| Zidovudine | The risk or severity of adverse effects can be increased when Zidovudine is combined with Prednisolone. |
| Oxaliplatin | The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Prednisolone. |
| Fluorouracil | The risk or severity of adverse effects can be increased when Fluorouracil is combined with Prednisolone. |
| Propylthiouracil | The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Prednisolone. |
| Pentostatin | The risk or severity of adverse effects can be increased when Pentostatin is combined with Prednisolone. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Prednisolone. |
| Clofarabine | The risk or severity of adverse effects can be increased when Clofarabine is combined with Prednisolone. |
| Pemetrexed | The risk or severity of adverse effects can be increased when Pemetrexed is combined with Prednisolone. |
| Mycophenolate mofetil | The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Prednisolone. |
| Dacarbazine | The risk or severity of adverse effects can be increased when Dacarbazine is combined with Prednisolone. |
| Temozolomide | The risk or severity of adverse effects can be increased when Temozolomide is combined with Prednisolone. |
| Penicillamine | The risk or severity of adverse effects can be increased when Penicillamine is combined with Prednisolone. |
| Azacitidine | The risk or severity of adverse effects can be increased when Prednisolone is combined with Azacitidine. |
| Carboplatin | The risk or severity of adverse effects can be increased when Prednisolone is combined with Carboplatin. |
| Dactinomycin | The risk or severity of adverse effects can be increased when Prednisolone is combined with Dactinomycin. |
| Azathioprine | The risk or severity of adverse effects can be increased when Prednisolone is combined with Azathioprine. |
| Hydroxyurea | The risk or severity of adverse effects can be increased when Prednisolone is combined with Hydroxyurea. |
| Mycophenolic acid | The risk or severity of adverse effects can be increased when Prednisolone is combined with Mycophenolic acid. |
| Topotecan | The risk or severity of adverse effects can be increased when Prednisolone is combined with Topotecan. |
| Mercaptopurine | The risk or severity of adverse effects can be increased when Prednisolone is combined with Mercaptopurine. |
| Thalidomide | The risk or severity of adverse effects can be increased when Prednisolone is combined with Thalidomide. |
| Melphalan | The risk or severity of adverse effects can be increased when Prednisolone is combined with Melphalan. |
| Fludarabine | The risk or severity of adverse effects can be increased when Prednisolone is combined with Fludarabine. |
| Flucytosine | The risk or severity of adverse effects can be increased when Prednisolone is combined with Flucytosine. |
| Capecitabine | The risk or severity of adverse effects can be increased when Prednisolone is combined with Capecitabine. |
| Procarbazine | The risk or severity of adverse effects can be increased when Prednisolone is combined with Procarbazine. |
| Arsenic trioxide | The risk or severity of adverse effects can be increased when Prednisolone is combined with Arsenic trioxide. |
| Idarubicin | The risk or severity of adverse effects can be increased when Prednisolone is combined with Idarubicin. |
| Estramustine | The risk or severity of adverse effects can be increased when Prednisolone is combined with Estramustine. |
| Mitoxantrone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Mitoxantrone. |
| Lomustine | The risk or severity of adverse effects can be increased when Prednisolone is combined with Lomustine. |
| Eculizumab | The risk or severity of adverse effects can be increased when Prednisolone is combined with Eculizumab. |
| Decitabine | The risk or severity of adverse effects can be increased when Prednisolone is combined with Decitabine. |
| Nelarabine | The risk or severity of adverse effects can be increased when Prednisolone is combined with Nelarabine. |
| Stepronin | The risk or severity of adverse effects can be increased when Prednisolone is combined with Stepronin. |
| Hydroxychloroquine | The risk or severity of adverse effects can be increased when Prednisolone is combined with Hydroxychloroquine. |
| Castanospermine | The risk or severity of adverse effects can be increased when Prednisolone is combined with Castanospermine. |
| Vorinostat | The risk or severity of adverse effects can be increased when Prednisolone is combined with Vorinostat. |
| 2-Methoxyethanol | The risk or severity of adverse effects can be increased when Prednisolone is combined with 2-Methoxyethanol. |
| Brequinar | The risk or severity of adverse effects can be increased when Prednisolone is combined with Brequinar. |
| Pirfenidone | The risk or severity of adverse effects can be increased when Prednisolone is combined with Pirfenidone. |
| Interferon alfa | The risk or severity of adverse effects can be increased when Prednisolone is combined with Interferon alfa. |
| Glatiramer | The risk or severity of adverse effects can be increased when Prednisolone is combined with Glatiramer. |
| Briakinumab | The risk or severity of adverse effects can be increased when Prednisolone is combined with Briakinumab. |
| Human interferon omega-1 | The risk or severity of adverse effects can be increased when Prednisolone is combined with Human interferon omega-1. |
| Mepolizumab | The risk or severity of adverse effects can be increased when Prednisolone is combined with Mepolizumab. |
| Abetimus | The risk or severity of adverse effects can be increased when Prednisolone is combined with Abetimus. |
| Belatacept | The risk or severity of adverse effects can be increased when Prednisolone is combined with Belatacept. |
| Bendamustine | The risk or severity of adverse effects can be increased when Prednisolone is combined with Bendamustine. |
| Pralatrexate | The risk or severity of adverse effects can be increased when Prednisolone is combined with Pralatrexate. |
| Wortmannin | The risk or severity of adverse effects can be increased when Prednisolone is combined with Wortmannin. |
| Eribulin | The risk or severity of adverse effects can be increased when Prednisolone is combined with Eribulin. |
| Belimumab | The risk or severity of adverse effects can be increased when Prednisolone is combined with Belimumab. |
| Teriflunomide | The risk or severity of adverse effects can be increased when Prednisolone is combined with Teriflunomide. |
| Carfilzomib | The risk or severity of adverse effects can be increased when Prednisolone is combined with Carfilzomib. |
| Dimethyl fumarate | The risk or severity of adverse effects can be increased when Prednisolone is combined with Dimethyl fumarate. |
| Obinutuzumab | The risk or severity of adverse effects can be increased when Prednisolone is combined with Obinutuzumab. |
| Vedolizumab | The risk or severity of adverse effects can be increased when Prednisolone is combined with Vedolizumab. |